The process of tracking itself often increases patient engagement with their health, leading to better overall outcomes
A 2023 analysis of GLP-1 users found that approximately 1525% of reproductive-age women experienced menstrual irregularity during the first three months of therapy, with the majority resolving by month six
It is not FDA-approved for insomnia or any medical condition, and the current evidence is insufficient to establish its efficacy or long-term safety
Unfortunately, weight regain is very common after initial weight loss
As hypertension development typically takes longer, study durations might be insufficient to capture GLP-1 RAs full effects on BP regulation
Gorio A, Di Giulio AM, Tenconi B, et al